Sarlósejtes vérszegénység: vizsgálatok itt: Franciaország
39 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 16.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleSafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Where
- Marseille, Nantes, Rouen Cedex, Toulouse
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07224360 · EU 2025-521154-42-00 - 4. fázisCsak meghívásosA Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
- Where
- Bordeau, Créteil, Lyon, Marseille, Paris
- Életkor
- 18 év and over
- People
- 55 worldwide
- Run by
- Agios Pharmaceuticals, Inc.
See details and how to joinNCT05777993 · EU 2026-526243-35-00 - 3. fázisNot yet taking people in FranciaországA Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
- Where
- Bordeaux, Creteil, Lyon Cedex 03, Marseille
- Életkor
- 12 év and over
- People
- 159 worldwide
- Run by
- Agios Pharmaceuticals, Inc.
See details and how to joinNCT07656415 · EU 2026-526778-18-00 - No phaseTaking peopleDevelopment of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
- Where
- Paris
- Életkor
- 18 év and over
- People
- 550
- Run by
- Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT06147414 - 3. fázisTaking peopleThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Where
- Créteil, Marseille, Paris, Toulouse
- Életkor
- 10 év to 65 év
- People
- 192 worldwide
- Run by
- Sanofi
See details and how to joinNCT06975865 - 2. fázisBefejeződöttSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- Where
- Bobigny, Bordeaux, Creteil, Lyon Cedex 03, Nantes, Rouen Cedex
- Életkor
- 12 év and over
- People
- 70 worldwide
- Run by
- CSL Behring
See details and how to joinNCT06699849 · EU 2024-513440-29-00 - 2. fázisTaking peoplePharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease
- Where
- Créteil, Jossigny, Le Kremlin-Bicêtre, Lyon, Paris, Saint-Denis
- Életkor
- 9 hónap to 11 év
- People
- 50 worldwide
- Run by
- Theravia
See details and how to joinNCT06578507 - No phaseNot yet taking people in FranciaországComparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS or SC Genotype (DrepAgreg)
- Where
- Bobigny
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Centre Hospitalier Universitaire de la Guadeloupe
See details and how to joinNCT07852442 - 3. fázisNot yet taking people in FranciaországA research study to evaluate how well etavopivat works in children with sickle cell disease
- Where
- Dijon, Grenoble Cedex 9, Paris
- Életkor
- Up to 17 év
- People
- 27 worldwide
- Run by
- Novo Nordisk A/S
See details and how to join2025-524464-38-00 - 2. fázisTaking peopleA Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
- Where
- Lyon, Paris, Rouen Cedex
- Életkor
- 6 hónap to 18 év
- People
- 95 worldwide
- Run by
- Forma Therapeutics, Inc.
See details and how to joinNCT06198712 · EU 2024-519881-32-00 - 3. fázisTaking peopleA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Where
- Creteil, Lyon Cedex 03, Paris
- Életkor
- 2 év and over
- People
- 480 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00 - 3. fázisTaking peopleA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Where
- Bobigny, Bordeaux, Creteil, Grenoble Cedex 9, Lyon Cedex 03, Paris, Rouen Cedex
- Életkor
- 12 év and over
- People
- 510 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00 - 3. fázisTaking peopleLidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
- Where
- Bordeaux, Lille, Marseille, Nantes, Orléans, Paris, Poitiers, Rouen, Toulouse, Tours
- Életkor
- 18 év and over
- People
- 104 worldwide
- Run by
- Nantes University Hospital
See details and how to joinNCT07274254 - 3. fázisTaking peopleLidocaine for opioid sparing in vaso-occlusive crisis of Sickle Cell Disease
- Where
- Bordeaux, Les Abymes, Lille Cedex, Marseille, Nantes, ORLEANS, Paris Cedex 20, Poitiers, Rouen, Talence, Toulouse Cedex 9, Tours
- Életkor
- 18 év and over
- People
- 104
- Run by
- Centre Hospitalier Universitaire De Nantes
See details and how to join2024-518437-28-00 - 2/3. fázisVisszavonvaA Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- Where
- Bobigny Cedex, Lyon, Toulouse Cedex 9
- Életkor
- 12 év to 64 év
- People
- 389 worldwide
- Run by
- Pfizer
See details and how to joinNCT05431088 · EU 2023-508766-14-00 - 1/2. fázisTaking peopleA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- Where
- Créteil, Marseille, Paris, Strasbourg
- Életkor
- 18 év and over
- People
- 224 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06481306 · EU 2023-510283-12-00 - No phaseNot yet taking people in FranciaországStandard of Care Comparative Arm of Phase 1/2 Gene Therapy Trial DREPAMIR" in Severe Sickle Cell Disease Patients
- Where
- Paris
- Életkor
- 12 év to 35 év
- People
- 30
- Run by
- Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07752043 - 2. fázisTaking peoplePharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children with Sickle Cell Disease: a single-group, non-randomised, open-label study (KID-BID)
- Where
- Cayenne, Creteil Cedex, Le Kremlin-Bicêtre, Meaux, Paris Cedex 15, St Denis Cedex
- Életkor
- Up to 17 év
- People
- 50
- Run by
- Theravia
See details and how to join2024-513750-30-00 - 3. fázisTaking peopleEfficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
- Where
- Bobigny Cedex, Colombes Cedex, Creteil, Créteil, Creteil Cedex, Le Kremlin-Bicetre, Lyon Cedex 03, Marseille, Paris, Rouen, Rouen Cedex, Toulouse Cedex 9
- Életkor
- 2 év and over
- People
- 130
- Run by
- Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT06818266 · EU 2023-505109-17-00 - No phaseNot yet taking people in FranciaországEpidemiology of Invasive Bacterial Infections in Children With Sickle Cell Disease in France Between 2020 and 2025
- Where
- Argenteuil, Aulnay-sous-Bois, Bondy, Bordeaux, Boulogne-Billancourt, Bry-sur-Marne, Cergy-Pontoise, Clamart, Corbeil-Essonnes, Créteil, Fontainebleau, Gonesse, Jossigny, Le Kremlin-Bicêtre, Mantes-la-Jolie, Marseille, Meaux, Melun, Montfermeil, Nantes, Neuilly-sur-Seine, Nice, Orsay, Paris, Poissy, Rambouillet, Saint-Denis, Versailles, Villeneuve-Saint-Georges
- Életkor
- Up to 17 év
- People
- 350
- Run by
- Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07639008 - 4. fázisFut, nem toborozRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- Where
- Paris
- Életkor
- 6 hónap to 100 év
- People
- 130 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04657822 · EU 2024-510734-41-00 - 3. fázisNot yet taking people in FranciaországEvaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease
- Where
- Amiens Cedex 1, Caen, Montivilliers, Rouen, Saint-Aubin-lès-Elbeuf
- Életkor
- 18 év and over
- People
- 144
- Run by
- University Hospital, Rouen
See details and how to joinNCT07498309 · EU 2025-522005-38-00 - No phaseTaking peopleMorphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care
- Where
- Créteil, Le Mans, Nantes, Orléans, Rennes, Tours
- Életkor
- 18 év and over
- People
- 100
- Run by
- University Hospital, Tours
See details and how to joinNCT07246265 · EU 2024-511985-34-00 - 1/2. fázisTaking peopleEfficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.
- Where
- Paris
- Életkor
- 12 év to 35 év
- People
- 15
- Run by
- Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07432867 - 3. fázisTaking peopleIntranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Emergency Department
- Where
- Aulnays-Sous-Bois, Bondy, Boulogne-Billancourt, Cayenne, Clamart, Colombes, Corbeil-Essonnes, Créteil, Le Coudray, Le Kremlin-Bicetre, Lille Cedex, Nantes, Saint-Denis
- Életkor
- Up to 17 év
- People
- 915
- Run by
- Assistance Publique Hopitaux De Paris
See details and how to join2023-504847-15-00